Hybrid Forecasting Intelligence
Hybrid human-machine forecasting for institutional investors
Independent Validation
- DARPA NGS2 Program: Methodology successfully replicated using out-of-sample datasets
- eBioMedicine (The Lancet): ML-augmentation framework peer-reviewed and published
- Journal of Financial Markets: Core forecasting methodology published
- Institutional Trials: Previous trials with major hedge funds informed our current systematic approach to signal generation
- 15-Year Track Record: Operational history across multiple forecasting domains
- 900+ Expert Network: Maintained across 15+ countries with dedicated relationship management
Live Macro Signals: December 2025
We are launching live macro divergence signals this December, providing real-time validation of our methodology's commercial application to US macroeconomic forecasting.
Leadership
Karl Mattingly, Founder & CEO: 25-year ANZ Bank career in senior risk and international banking, followed by 17 years developing classified and commercial intelligence systems. MBA Columbia University.
Prof. Anne-Louise Ponsonby, Chief Scientist: Principal Investigator at University of Melbourne and The Florey Institute. Leading scientific validation and academic collaboration efforts.
Stephen Markscheid, Founder & Director: 35+ years international experience at Boston Consulting Group and General Electric. MBA Columbia, MA Johns Hopkins SAIS.
Institutional Conversations
We work with sophisticated institutional investors who understand the value of alternative intelligence sources. Our approach to client relationships is built on transparency, scientific rigor, and operational excellence.